Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 407

1.
2.

Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.

Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1043-8. Epub 2004 Apr 22.

3.

Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humans.

Witherow FN, Dawson P, Ludlam CA, Webb DJ, Fox KA, Newby DE.

Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1667-70. Epub 2003 Jul 17.

4.
5.

B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.

Cruden NL, Tse GH, Fox KA, Ludlam CA, Megson I, Newby DE.

Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):772-7. Epub 2005 Jan 27.

6.

Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure.

Davie AP, Dargie HJ, McMurray JJ.

Circulation. 1999 Jul 20;100(3):268-73.

7.

Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.

Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ.

J Am Coll Cardiol. 2001 Nov 1;38(5):1402-8.

8.

Vascular B1 kinin receptors in patients with congestive heart failure.

Lang NN, Cruden NL, Tse GH, Bloomfield P, Ludlam CA, Fox KA, Newby DE.

J Cardiovasc Pharmacol. 2008 Nov;52(5):438-44. doi: 10.1097/FJC.0b013e31818c66cb.

PMID:
19033823
9.

Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.

Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM.

Br J Clin Pharmacol. 1994 Oct;38(4):317-21.

10.

Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.

Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM.

J Cardiovasc Pharmacol. 1993 Oct;22(4):579-84.

PMID:
7505360
12.

Bradykinin does not contribute to peripheral vascular tone in patients with cirrhosis and ascites.

Helmy A, Ferguson JW, Hayes PC, Newby DE, Webb DJ.

J Cardiovasc Pharmacol. 2006 Apr;47(4):556-60.

PMID:
16680069
13.
14.

Effects of bradykinin on venous capacitance in health and treated chronic heart failure.

Gunaruwan P, Maher A, Williams L, Sharman J, Schmitt M, Campbell R, Frenneaux M.

Clin Sci (Lond). 2009 Mar;116(5):443-50. doi: 10.1042/CS20080096.

15.

Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.

Newby DE, Goodfield NE, Flapan AD, Boon NA, Fox KA, Webb DJ.

Heart. 1998 Aug;80(2):134-40.

16.

Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients.

Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A.

J Hypertens. 1998 Apr;16(4):447-56.

PMID:
9797190
17.

Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability.

Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ.

Br J Clin Pharmacol. 1997 May;43(5):493-9.

19.
20.

Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.

van Wijngaarden J, Smit AJ, de Graeff PA, van Gilst WH, van der Broek SA, van Veldhuisen DJ, Lie KI, Wesseling H.

J Cardiovasc Pharmacol. 1994 Feb;23(2):240-5.

PMID:
7511753

Supplemental Content

Support Center